-- Mary Elizabeth Dallas
FRIDAY, May 31 (HealthDay News) -- Researchers have identified a
new class of drugs that show promise for treating advanced prostate
cancer. The drugs, known as peptidomimetics, interfere with the
signaling necessary for prostate cancer cells to grow, according to
a new study.
Prostate cancer depends upon the actions of androgens, such as
the hormone testosterone. Androgens activate androgen receptors,
resulting in a signal that causes prostate cancer cells to
To stop tumor growth, men with prostate cancer have been treated
with drugs to block the production of androgens or block the
receptor where androgens bind. However, tumors can grow despite
this treatment because of mutations in androgens or receptors.
In the latest study, published online May 28 in
Nature Communications, a team of researchers led by Dr.
Ganesh Raj, associate professor of urology at UT Southwestern
Medical Center at Dallas, found the nontoxic peptidomimetic agents
could disrupt androgen-receptor signaling and prevent tumor
When tested in mouse and human tissue models, the drugs blocked
the activity of androgens by attacking the protein in a different
spot from where the androgen binds, the researchers explained. As a
result, prostate cancer cells do not receive the signal to grow --
even when the androgen receptor is activated.
"We are hopeful that this novel class of drugs will shut down androgen-receptor signaling and lead to added options and increased longevity for men with advanced prostate cancer," Raj, the study's senior author, noted in a university news release.
One expert was optimistic about the new findings.
"The study represents a significant step forward in the development of a new molecular targeted therapy for advanced prostate cancer," said Dr. Manish Vira, director of the Fellowship Program in Urologic Oncology at North Shore-LIJ's Arthur Smith Institute for Urology in Lake Success, N.Y.
He said the new drug works at "preventing the [cell] receptor
from promoting cancer cell growth signaling," and added that "the
study is proof in principle that rationale design of
peptidomimetics can lead to the development of a new class of
The researchers noted more testing is needed before the drugs
could progress to clinical trials involving humans. Results
obtained in laboratory experiments are not always replicated in
"Most drugs now available to treat advanced prostate cancer improve survival rates by three or four months," Raj added. "Our new agents may offer hope for men who fail with the current drugs."
The U.S. National Cancer Institute has more about
treatment for prostate cancer.
EBSCO Information Services is fully accredited by URAC. URAC is an independent, nonprofit health care accrediting organization dedicated to promoting health care quality through accreditation, certification and commendation.
Please be aware that this information is provided to supplement the care provided by your physician. It is neither intended nor implied to be a substitute for professional medical advice. CALL YOUR HEALTHCARE PROVIDER IMMEDIATELY IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY. Always seek the advice of your physician or other qualified health provider prior to starting any new treatment or with any questions you may have regarding a medical condition.
Copyright © EBSCO Information Services. All rights reserved.